- Home
- PCRX
as 05-30-2025 4:00pm EST
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | TAMPA |
| Market Cap: | 1.2B | IPO Year: | 2011 |
| Target Price: | $29.89 | AVG Volume (30 days): | 891.6K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.16 - $31.64 | Next Earning Date: | 05-08-2025 |
| Revenue: | $702,772,000 | Revenue Growth: | 3.08% |
| Revenue Growth (this year): | 8.63% | Revenue Growth (next year): | 11.66% |
Latest Pacira BioSciences Inc. News
PCRX Breaking Stock News: Dive into PCRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
Pacira BioSciences (NASDAQ:PCRX) adds US$78m to market cap in the past 7 days, though investors from three years ago are still down 57%
Argus Research
11 days ago
PCRX: Raising target price to $29.00
GlobeNewswire
17 days ago
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
GlobeNewswire
18 days ago
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Argus Research
18 days ago
PCRX: Lowering target price to $26.00
Zacks
23 days ago
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates
GuruFocus.com
23 days ago
Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ...
Associated Press Finance
23 days ago
Pacira: Q1 Earnings Snapshot
Compare PCRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PCRX Pacira BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.